RESULTS
A total of 66 subjects were assessed for inclusion;
20 were excluded prior to study initiation. Therefore,
46 healthy Chinese males (mean [SD] age, 24.1
[2.5] years [range, 20–30 years]; height, 170.8 [5.1] cm
[range, 160–180 cm]; weight, 64.6 [6.4] kg [range,
55–77 kg]; BMI, 22.1 [1.7] kg/m2 [range, 19.2–
24.9 kg/m2]) were enrolled and completed the study.
During the study, 1 subject was mistakenly administered
the same formulation in both administration periods.
Therefore, 45 subjects (mean [SD] age, 24.1 [2.5] years
[range, 20–30 years]; height, 171.1 [4.9] cm [range,
160–180 cm]; weight, 64.8 [6.3] kg [range, 55.5–
77.0 kg]; BMI, 22.1 [1.7] kg/m2 [range, 19.2–24.9 kg/m2])
were included in the pharmacokinetic and bioequivalent
analyses. All 46 subjects were included in the tolerability
assessment.